A Case of Chronic Conjunctivitis following Rituximab Therapy
The activity of the anti-CD20 monoclonal antibody, rituximab in B-cell non-Hodgkin's lymphoma, with relatively minimal toxicity has been well established. Adverse effects such as low-grade fever, urticaria, bronchospasm, sporadic tachycardia, and hypotension have been described. However, only a...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2009-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2009/272495 |
id |
doaj-4bf039cb4c494c6f80d8f6a5bb0df725 |
---|---|
record_format |
Article |
spelling |
doaj-4bf039cb4c494c6f80d8f6a5bb0df7252021-07-02T05:50:12ZengHindawi LimitedAdvances in Hematology1687-91041687-91122009-01-01200910.1155/2009/272495272495A Case of Chronic Conjunctivitis following Rituximab TherapyMarnelli A. Bautista0Walter D. Y. Quan1Jun Wang2Department of Pathology and Laboratory Medicine, Loma Linda University Medical Center, 11234 Anderson Street, Loma Linda, CA 92354, USADivision of Medical Oncology, Department of Internal Medicine, Loma Linda University School of Medicine, 11175 Campus Street, Chan Shun Pavilion 11015, Loma Linda, CA 92354, USADepartment of Pathology and Laboratory Medicine, Loma Linda University Medical Center, 11234 Anderson Street, Loma Linda, CA 92354, USAThe activity of the anti-CD20 monoclonal antibody, rituximab in B-cell non-Hodgkin's lymphoma, with relatively minimal toxicity has been well established. Adverse effects such as low-grade fever, urticaria, bronchospasm, sporadic tachycardia, and hypotension have been described. However, only a single case of rituximab-related, transient conjunctivitis has been documented in literature. We report an occurrence of chronic, bilateral conjunctivitis in an 88-year-old female diagnosed with stage IV, non-Hodgkin's lymphoma (NHL), who was maintained on rituximab for 12 months. In contrast to the previously described case, our patient developed severe conjunctival inflammation approximately three to four weeks following rituximab induction. Resolution of conjunctivitis occurred within two months after cessation of rituximab treatment.http://dx.doi.org/10.1155/2009/272495 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Marnelli A. Bautista Walter D. Y. Quan Jun Wang |
spellingShingle |
Marnelli A. Bautista Walter D. Y. Quan Jun Wang A Case of Chronic Conjunctivitis following Rituximab Therapy Advances in Hematology |
author_facet |
Marnelli A. Bautista Walter D. Y. Quan Jun Wang |
author_sort |
Marnelli A. Bautista |
title |
A Case of Chronic Conjunctivitis following Rituximab Therapy |
title_short |
A Case of Chronic Conjunctivitis following Rituximab Therapy |
title_full |
A Case of Chronic Conjunctivitis following Rituximab Therapy |
title_fullStr |
A Case of Chronic Conjunctivitis following Rituximab Therapy |
title_full_unstemmed |
A Case of Chronic Conjunctivitis following Rituximab Therapy |
title_sort |
case of chronic conjunctivitis following rituximab therapy |
publisher |
Hindawi Limited |
series |
Advances in Hematology |
issn |
1687-9104 1687-9112 |
publishDate |
2009-01-01 |
description |
The activity of the anti-CD20 monoclonal antibody, rituximab in B-cell non-Hodgkin's lymphoma, with relatively minimal toxicity has been well established. Adverse effects such as low-grade fever, urticaria, bronchospasm, sporadic tachycardia, and hypotension have been described. However, only a single case of rituximab-related, transient conjunctivitis has been documented in literature. We report an occurrence of chronic, bilateral conjunctivitis in an 88-year-old female diagnosed with stage IV, non-Hodgkin's lymphoma (NHL), who was maintained on rituximab for 12 months. In contrast to the previously described case, our patient developed severe conjunctival inflammation approximately three to four weeks following rituximab induction. Resolution of conjunctivitis occurred within two months after cessation of rituximab treatment. |
url |
http://dx.doi.org/10.1155/2009/272495 |
work_keys_str_mv |
AT marnelliabautista acaseofchronicconjunctivitisfollowingrituximabtherapy AT walterdyquan acaseofchronicconjunctivitisfollowingrituximabtherapy AT junwang acaseofchronicconjunctivitisfollowingrituximabtherapy AT marnelliabautista caseofchronicconjunctivitisfollowingrituximabtherapy AT walterdyquan caseofchronicconjunctivitisfollowingrituximabtherapy AT junwang caseofchronicconjunctivitisfollowingrituximabtherapy |
_version_ |
1721338154718330880 |